CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
chiauranib +2 moredrug
Likely dose
chiauranib 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03901118
NCT03901118Phase 2Completed
CompareCT.gov

A Multi-center, Phase Ⅱ Clinical Trial of Chiauranib Plus Chemotherapy in Relapsed/Refractory Ovarian Cancer

Chipscreen Biosciences, Ltd.·interventional·Posted Apr 3, 2019·Updated Mar 19, 2021

In Brief

A Phase 2 clinical trial evaluating chiauranib, etoposide, and 1 other intervention for Ovarian Cancer. Completed, enrolled 47 participants across 1 site.

Detailed Summary

This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 3, 2019
Enrollment StartJul 1, 2019
Primary CompletionDec 18, 2020
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 7.2 years ago

Interventions

chiauranibdrug

in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily

etoposidedrug

50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most

paclitaxeldrug

60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most